



budesonide 9mg prolonged release tablet (Cortiment®)

Ferring Pharmaceuticals Ltd

10 December 2021

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and, following review by the SMC executive, advises NHS Boards and Area Drug and Therapeutics Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows:

ADVICE: following an abbreviated submission

budesonide (Cortiment®) is accepted for use within NHSScotland.

Indication under review: Induction of remission in patients with active microscopic colitis.
Induction of remission in patients with active microscopic colitis.

Cortiment® offers a prolonged release formulation of budesonide for this indication. Other oral budesonide formulations are available at lower cost.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

This assessment is based on data submitted by the applicant company up to and including 11 November 2021.

**Chairman
Scottish Medicines Consortium**